Mavrilimumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mavrilimumab
Accession Number
DB12534
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • CAM-3001
Categories
UNII
1158JD1P9A
CAS number
1085337-57-0

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Mavrilimumab.
AbituzumabThe risk or severity of adverse effects can be increased when Mavrilimumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Mavrilimumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Mavrilimumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Mavrilimumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Mavrilimumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mavrilimumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Mavrilimumab.
AmatuximabThe risk or severity of adverse effects can be increased when Mavrilimumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Mavrilimumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911343
Wikipedia
Mavrilimumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentRheumatoid Arthritis3
2TerminatedTreatmentRheumatoid Arthritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 16:45 / Updated on November 02, 2018 07:26